CPC C07K 16/2803 (2013.01) [C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); C07K 16/40 (2013.01); C12Q 1/6886 (2013.01); C12Y 113/11052 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55 (2013.01); C07K 2317/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)] | 30 Claims |
1. A method of treating colorectal cancer in a human patient, the method comprising
testing or having tested a biological sample obtained from a patient having colorectal cancer, thereby determining that the patient's colorectal cancer is microsatellite instability high or DNA mismatch repair deficient; and
in response to determining that the colorectal cancer is microsatellite instability high or DNA mismatch repair deficient, treating the patient determined to have microsatellite instability high or DNA mismatch repair deficient colorectal cancer with a therapeutically effective amount of an anti-PD-1 antibody.
|